Appendiceal neoplasms

1. Overview

Appendiceal neoplasms are a rare and heterogeneous group of tumors arising from the vermiform appendix. While the appendix is historically known for acute appendicitis, neoplastic processes account for approximately 0.5% to 1% of all appendiceal specimens removed during appendectomy and roughly 0.5% of all gastrointestinal malignancies.

Despite their rarity, the clinical significance of these tumors has grown considerably due to advances in cross-sectional imaging, the advent of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), and a refined understanding of their unique biological behavior—particularly the spectrum of mucinous neoplasms.

Unlike colonic adenocarcinoma, which follows a classic adenoma-carcinoma sequence, appendiceal neoplasms encompass distinct pathological entities ranging from benign neuroendocrine tumors (carcinoids) to low-grade mucinous neoplasms with indolent but pervasive intraperitoneal spread (pseudomyxoma peritonei), and aggressive adenocarcinomas resembling colorectal cancer. Accurate diagnosis, staging, and multidisciplinary management are paramount, as treatment strategies diverge significantly from standard colorectal protocols.

2. Epidemiology and Risk Factors

Incidence and Demographics

• Overall Incidence: Estimated at 1.2 per 100,000 person-years.
• Age Distribution: Bimodal distribution depending on histology.
• Neuroendocrine tumors (NETs): Peak incidence in the 4th decade (mean age ~40 years).
• Mucinous neoplasms & Adenocarcinomas: Peak incidence in the 5th–6th decades (mean age ~55–60 years).
• Sex Predilection: Slight female predominance for mucinous neoplasms and goblet cell adenocarcinoma; roughly equal distribution for NETs and colonic-type adenocarcinoma.
• Trends: Incidence appears to be rising, likely due to increased utilization of cross-sectional imaging (CT/MRI) detecting incidental lesions and improved pathological classification.

Etiology and Risk Factors

The etiology remains poorly understood. Unlike colorectal cancer, strong hereditary syndromes are less frequently implicated, though associations exist:

Most appendiceal neoplasms arise sporadically without identifiable risk factors.

3. Histopathological Classification (WHO 2019/2022 Updates)

The World Health Organization (WHO) classification is the gold standard. It separates tumors by cell lineage (epithelial vs. neuroendocrine) and, crucially for epithelial tumors, by grade and invasive potential rather than just “benign vs. malignant.”

Neuroendocrine Neoplasms (NENs)

• Neuroendocrine Tumor (NET) Grade 1 (Well-differentiated): Formerly “Carcinoid.” Ki-67 < 3%, mitotic count < 2/10 HPF. Most common appendiceal neoplasm (~50-65%).
• Neuroendocrine Tumor (NET) Grade 2 (Well-differentiated): Ki-67 3–20%, mitotic count 2–20/10 HPF. Rare in appendix.
• Neuroendocrine Carcinoma (NEC) Grade 3 (Poorly differentiated): Small cell or large cell type. Ki-67 > 20%. Extremely rare, highly aggressive.

Epithelial Neoplasms: The Mucinous Spectrum

This is the most complex and clinically critical category. Terminology has shifted away from “adenoma vs. carcinoma” toward grade and invasion status.

Other Rare Types

• Serrated Lesions: Sessile serrated lesions (SSL), Traditional serrated adenoma (TSA).
• Mesenchymal Tumors: GIST, Leiomyosarcoma, Lymphoma (rare primary).
• Metastases to Appendix: Most commonly from ovary (Krukenberg), breast, colon, stomach.

4. How Does It Look? (Gross & Radiological Appearance)

Understanding the visual phenotype is critical for radiologists, surgeons, and pathologists to avoid misclassification.

Gross Pathology (Macroscopic Appearance)

A. Neuroendocrine Tumors (NETs)

• Location: Tip of the appendix (75%), less commonly body/base.
• Appearance: Small (< 1 cm usually), yellow-tan, firm, submucosal nodules with a smooth, intact overlying mucosa.
• Key Feature: Often described as a “bead” or “pearl” in the appendiceal wall. Rarely ulcerate unless large (>2 cm).
• Mesenteric Fat: May show “spiculation” or desmoplastic reaction radiating from the tumor (especially >1 cm).

B. Low-Grade Appendiceal Mucinous Neoplasm (LAMN)

• Appearance: Distended, “sausage-shaped” appendix (mucocele). Diameter often > 2 cm.
• Wall: Thin, attenuated, translucent, or thickened/fibrotic.
• Content: Copious gelatinous, sticky mucus (acellular or low cellularity).
• Mucosa: Villous/papillary projections lining the lumen (villous adenoma appearance). No frank mass or necrosis.
• Critical Finding: Perforation/Rupture. Look for mucus tracking along the serosa, mesoappendix, or free in the peritoneal cavity.

C. High-Grade Appendiceal Mucinous Neoplasm (HAMN)

• Grossly indistinguishable from LAMN. Diagnosis is strictly microscopic.

D. Mucinous Adenocarcinoma (MAC)

• Appearance: Mucinous mass, often larger than LAMN.
• Wall: Thickened, irregular, shaggy, or necrotic.
• Invasion: Grossly visible invasion through the wall into peri-appendiceal fat or adjacent organs (cecum, terminal ileum, ovary).
• Content: Mucin mixed with solid tumor nodules (“scirrhous” areas).

E. Goblet Cell Adenocarcinoma (GCA)

• Location: Often base/body of appendix (vs tip for NET).
• Appearance: Circumferential wall thickening (“napkin ring” or “apple core” lesion), firm, gray-white.
• Mucus: Usually less copious extracellular mucin than LAMN/MAC; mucin is often intracellular.
• Mucosa: Often ulcerated.

F. Colonic-type Adenocarcinoma

• Location: Base of appendix.
• Appearance: Annular constricting mass, polypoid mass, or ulcerated lesion resembling colonic cancer. Often obstructs the appendiceal orifice.

Cross-Sectional Imaging (CT / MRI)

CT Abdomen/Pelvis with IV and Oral Contrast is the primary staging modality. MRI is superior for mucin characterization and peritoneal surface disease (PSD) mapping.

The “Mucocele” Sign (LAMN / HAMN / MAC)

• CT: Well-capsulated, spherical or tubular cystic mass in RLQ, continuous with cecum.
• Internal Attenuation: Low attenuation (water density: 0–20 HU) for simple mucus. Higher attenuation (20–50 HU) suggests high protein content, hemorrhage, or cellularity (worrisome for MAC/HAMN).
• Wall: Thin, smooth, enhancing wall = Benign/LAMN.
• Wall: Thick (>3mm), irregular, nodular, enhancing = Malignant (MAC/HAMN/GCA).
• Curvilinear/Wall Calcification: “Eggshell” or “onion-skin” calcification is highly specific for mucocele (often LAMN), but does not exclude malignancy.

Pseudomyxoma Peritonei (PMP) / Peritoneal Dissemination

• “Scalloping” of Visceral Surfaces: Mucin deposits indenting liver, spleen, pelvic sidewalls.
• “Omental Caking” / “Ommental Cake”: Thickened, nodular, enhancing omentum infiltrated by mucin/tumor.
• Mucin Attenuation on CT: Variable. “High-attenuation mucin” (>20 HU) correlates with higher cellularity/grade.
• MRI (T2-weighted): High signal intensity (bright) for acellular mucin (LAMN/PMP low-grade). Intermediate/Lower signal for cellular mucin/tumor nodules (High-grade PMP/MAC/GCA). Diffusion-weighted imaging (DWI) restricts diffusion in cellular deposits.

Goblet Cell Adenocarcinoma (GCA) Specifics

• Circumferential wall thickening of appendix/base of cecum.
• Mesenteric stranding and lymphadenopathy (more common than in LAMN).
• Ovarian metastases (bilateral, cystic/solid) – “Krukenberg-like” appearance.

Neuroendocrine Tumor (NET) Imaging

• Often occult on CT if < 1 cm.
• Somatostatin Receptor Imaging (Ga-68 DOTATATE PET/CT): Gold standard for staging well-differentiated NETs (Grade 1/2). High sensitivity for primary and metastatic disease.
• FDG PET/CT: Poor sensitivity for Grade 1 NETs (low metabolic rate). Essential for Grade 3 NEC.

Endoscopic Appearance (Colonoscopy)

• Incidental Finding: Seen in < 1% of colonoscopies.
• Appendiceal Orifice: Look for mucus extrusion (“volcano sign”), bulging orifice, mucosal granularity, or a polypoid mass protruding from the orifice.
• Intussusception: Appendix inverting into cecum (can be caused by NET or LAMN).
• Biopsy Risk: Superficial biopsies are often non-diagnostic for LAMN/HAMN/MAC because the neoplasm is submucosal or the mucosa is attenuated. Deep biopsies risk perforation. Biopsy is generally discouraged if mucocele/LAMN suspected on imaging. Biopsy is appropriate for suspicious masses (GCA, Adenocarcinoma) to confirm histology pre-op.

5. Symptoms and Clinical Presentation

The clinical presentation is highly variable and dictated by tumor histology, size, location, and presence of perforation or metastatic spread. A significant proportion are incidental findings.

Asymptomatic / Incidental Discovery (30–50% of cases)

• Found on imaging for unrelated reasons (renal colic, trauma, gynecologic workup).
• Found at pathology after appendectomy for “acute appendicitis.”
• Found on screening colonoscopy (mucus at orifice, bulge).

Acute Appendicitis Mimic (Most Common Symptomatic Presentation: 50–60%)

Mechanism: Tumor obstructs the appendiceal lumen → distension → ischemia → inflammation.

• Symptoms: Classic RLQ pain, anorexia, nausea, low-grade fever, leukocytosis.
• Demographics: Often younger patients (NETs) or older (Epithelial).
• Clinical Pitfall: Surgeon performs laparoscopic appendectomy for “appendicitis.”
• If NET < 1-2 cm at tip: Curative usually.
• If LAMN/MAC: Risk of intraoperative spillage/rupture converting a localized disease (Stage I) to disseminated disease (Stage IV/PMP). Frozen section is critical.

Symptoms of Mucinous Neoplasms & Pseudomyxoma Peritonei (PMP)

These develop insidiously over months/years due to progressive intraperitoneal mucin accumulation.

Clinical Pearl: “The Appendix is the primary until proven otherwise.” In a woman with a mucinous ovarian mass and** an appendiceal lesion/mucocele, the appendix is the primary (Krukenberg tumor equivalent). Immunohistochemistry (CK20+, CDX2+, SATB2+, PAX8-, ER-, WT1-) confirms appendiceal origin.

Symptoms of Goblet Cell Adenocarcinoma (GCA)

• Hybrid presentation: Can present as acute appendicitis (obstruction) OR chronic RLQ mass/pain (infiltrative growth).
• Higher rate of lymph node metastasis and ovarian metastasis at presentation compared to LAMN.
• Intussusception: More common with GCA/NET at base than LAMN.

Symptoms of Colonic-type Adenocarcinoma

• Mimics cecal carcinoma: Iron deficiency anemia (occult bleeding), change in bowel habits, weight loss, palpable RLQ mass.
• Less mucin production → less PMP, more hematogenous spread (liver/lung).

Symptoms of Neuroendocrine Tumors (NETs)

• < 1 cm (Tip): Almost always asymptomatic / incidental.
• 1–2 cm (Tip/Body): Acute appendicitis symptoms.
• > 2 cm or Base location: RLQ mass, chronic pain, intussusception.
• Carcinoid Syndrome: Exceedingly rare from primary appendiceal NET (< 1%). Requires liver metastases (bypassing portal venous drainage) or primary ovarian/teratoma NET. Symptoms: Flushing, diarrhea, valvular heart disease (right-sided), bronchospasm.

6. Diagnostic Workup Algorithm

Laboratory Studies

Imaging Staging (Baseline)

1. CT Chest/Abdomen/Pelvis with Contrast: Standard for all epithelial neoplasms. Assess primary tumor (wall thickness, enhancement, calcification), nodes, liver mets, peritoneal carcinomatosis (PCI score estimation), extra-abdominal mets.
2. MRI Pelvis/Abdomen (with DWI): Preferred for PMP/LAMN/MAC. Superior soft tissue contrast for peritoneal deposits, mucin characterization (cellular vs acellular), and pelvic organ invasion. Used for Peritoneal Cancer Index (PCI) calculation planning.
3. Ga-68 DOTATATE PET/CT: Mandatory for NET Grade 1/2 (staging, detecting occult mets). Optional for GCA (variable SSTR expression).
4. FDG PET/CT: Mandatory for MAC, GCA (High grade), Colonic-type, NEC Grade 3. Not useful for LAMN/HAMN/Low-grade PMP (low metabolic activity).
5. Diagnostic Laparoscopy: Gold standard for PCI assessment in mucinous neoplasms prior to committing to CRS/HIPEC. Detects occult peritoneal disease missed by CT/MRI (sensitivity CT ~75-85% vs Lap >95%).

Pathology & Molecular Testing (Essential)

• AJCC 8th Edition Staging: Specific appendix chapter (separate from colon).
• Immunohistochemistry (IHC) Panel:
• Appendiceal Epithelial: CK20+, CDX2+, SATB2+, MUC2+, MUC5AC+.
• Ovarian Primary (Differential): PAX8+, WT1+, ER+, CK7+, CK20-.
• NET: Synaptophysin+, Chromogranin A+, Ki-67 index (mandatory).
• GCA: Dual staining: Neuroendocrine markers (Synaptophysin, CD56) + Glandular markers (CK20, CDX2, MUC2). Ki-67 critical for grading.
• Molecular Profiling (All Adenocarcinomas/GCA):
• MMR/MSI Status (IHC or PCR): Lynch screening. dMMR/MSI-H seen in ~10-15% appendiceal adenocarcinomas (higher in younger patients). Predicts immunotherapy response.
• RAS (KRAS/NRAS) / BRAF V600E: Mutational status. KRAS mutated in ~40-50% MAC/GCA. BRAF V600E rare but prognostic. Guides anti-EGFR therapy (cetuximab/panitumumab) in metastatic setting (only if RAS WT).
• HER2 Amplification: Emerging target (trastuzumab deruxtecan).
• NTRK Fusions: Rare but targetable (larotrectinib/entrectinib).

7. Staging Systems

AJCC 8th Edition TNM (Epithelial Neoplasms)

Unique feature: pTis LAMN category exists. No pTis for HAMN/MAC.

Staging for NETs (ENETS / AJCC)

• T1: ≤ 1 cm (Tip usually T1a, Base T1b).
• T2: > 1 cm ≤ 2 cm.
• T3: > 2 cm ≤ 4 cm.
• T4: > 4 cm or invasion of adjacent organs.
• Nodal status critical for >1 cm tumors.

Peritoneal Cancer Index (PCI) – For Mucinous Neoplasms/PMP

Used to quantify disease burden for CRS/HIPEC eligibility.

• 13 Regions (0-12) + Small Bowel (4 regions) = Max score 39.
• Lesion Size Score (LS): LS-0 (none), LS-1 (<0.5cm), LS-2 (0.5-5cm), LS-3 (>5cm).
• PCI = Sum of LS for all 13 regions.
• Prognostic Cutoffs:
• PCI ≤ 10-12: Excellent candidates for CRS/HIPEC (Long-term survival >60-80% at 10yr for LAMN).
• PCI 13-20: Selected candidates (depends on histology grade, resectability).
• PCI > 20: Generally poor candidates for curative CRS/HIPEC (palliative intent).

8. Management Strategies: A Histology-Driven Approach

Management is not “one size fits all.” It requires a Multidisciplinary Tumor Board (MDT) including Surgical Oncology, Medical Oncology, Radiology, Pathology, and HIPEC specialists.

Neuroendocrine Tumors (NETs)

Low-Grade Mucinous Neoplasms (LAMN) & Pseudomyxoma Peritonei (PMP – Low Grade / DPAM)

A. LAMN Confined to Appendix (pTis LAMN, No Rupture, Margins Negative)

• Treatment: Simple Appendectomy alone is curative.
• Surveillance: Controversial. Most guidelines: No routine imaging surveillance if completely resected (R0). Some suggest CT at 12-24 months. Lifetime risk of recurrence near zero if truly confined R0.

B. LAMN with Rupture / Positive Margins / Mucin Spillage at Surgery

• Risk: Development of PMP (Disseminated Peritoneal Adenomucinosis – DPAM).
• Management:

1. Observation (Watch & Wait): For minimal spillage, low PCI, asymptomatic. Serial CT/MRI + Tumor markers (CEA, CA 19-9) q 6 mo x 3-5 yrs.
2. Prophylactic CRS/HIPEC: Considered in high-volume centers for documented gross spillage or positive margins to prevent future PMP. Controversial; morbidity of CRS/HIPEC vs risk of PMP (15-30%).
3. Diagnostic Laparoscopy + PCI: At 6-12 months to assess peritoneal status.

C. Established PMP (Low Grade / DPAM)

• Standard of Care: Complete Cytoreductive Surgery (CRS) + HIPEC.
• Goal: CC-0 / CC-1 (No visible disease / Nodules < 2.5mm).
• HIPEC Agent: Mitomycin C (MMC) is standard for low-grade (40-42°C, 90 min). Oxaliplatin alternative.
• Outcomes: 10-year OS 60-90% in high-volume centers. Recurrence common but often manageable with repeat CRS/HIPEC.
• Inoperable / High PCI / Frail: “Watchful waiting,” serial paracentesis, nutritional support, palliative systemic therapy (rarely effective for low-grade).

High-Grade Mucinous Neoplasms (HAMN) & Mucinous Adenocarcinoma (MAC) / Colonic-type / Signet Ring Cell

A. Localized Disease (Stage I-III, M0)

• Surgery: Right Hemicolectomy with Adequate Lymphadenectomy (≥12 nodes). Simple appendectomy is insufficient due to nodal risk and risk of lymphovascular invasion.
• Adjuvant Chemotherapy:
• Stage II (T3-T4, N0): Controversial. Consider for T4, perforation, signet ring, LVI, <12 nodes, high grade. CAPOX / FOLFOX x 3-6 months.
• Stage III (N+): Strongly Recommended. CAPOX or FOLFOX x 6 months (IDEA collaboration data extrapolated from colon).
• dMMR/MSI-H: May omit adjuvant chemo in Stage II (like colon), benefit in Stage III debated.

B. Metastatic Disease (Stage IV / M1)

• M1a (Peritoneal Only – PMCA):
• CRS/HIPEC considered only if Complete Cytoreduction (CC-0/1) achievable AND Low Volume (PCI < 15-20) AND Favorable Biology (not signet ring, not high grade MAC).
• HIPEC Agent: Oxaliplatin (460 mg/m2, 30 min) preferred for high-grade/high cellularity (PRODIGE 7 / PROPHYLOCHIP data context).
• If unresectable: Systemic Chemotherapy (FOLFOX/FOLFIRI ± Bevacizumab). Immunotherapy if dMMR/MSI-H (Pembrolizumab/Dostarlimab).
• M1b/c (Hematogenous ± Peritoneal):
• Systemic Therapy: FOLFOX/CAPOX or FOLFIRI ± Bevacizumab (1st line).
• RAS WT: Add Anti-EGFR (Cetuximab/Panitumumab) (evidence extrapolated from CRC; benefit seen in appendiceal RAS WT).
• dMMR/MSI-H: Immune Checkpoint Inhibitors (Pembrolizumab) 1st line preferred.
• HER2+: Trastuzumab Deruxtecan (T-DXd) or Tucatinib/Trastuzumab (emerging).
• Later lines: Regorafenib, TAS-102 (Trifluridine/Tipiracil), Clinical Trials.

Goblet Cell Adenocarcinoma (GCA) – Unique Strategy

• Behavior: Intermediate between NET and Adenocarcinoma. High propensity for ovarian mets, peritoneal spread, nodal mets.
• Localized (Any Size): Right Hemicolectomy + Bilateral Salpingo-Oophorectomy (BSO) in females (high occult ovarian mets rate ~30-50%). Omentectomy. Appendectomy alone inadequate.
• Staging: CT + DOTATATE PET (SSTR often positive) + FDG PET.
• Adjuvant Chemo: Recommended for Stage II/III (CAPOX/FOLFOX). Benefit clearer than in LAMN.
• Metastatic:
• Peritoneal (M1a): CRS/HIPEC (Oxaliplatin) if resectable (CC-0/1). Outcomes intermediate (5-yr OS ~40-50%).
• Systemic: Treat as Adenocarcinoma (FOLFOX/Bev). SSTR-targeted therapy (PRRT / SSA) may have role in well-differentiated (Low Grade) GCA with high SSTR expression.
• Grade 3 (High Grade): Treat as high-grade adenocarcinoma (Platinum-based? FOLFOX? Clinical trials).

9. Cytoreductive Surgery (CRS) & HIPEC: Technical Nuances

This is a high-morbidity procedure (Major Complication Rate 20-40%, Mortality 1-3% in expert centers) performed only in specialized high-volume centers (>20 cases/year).

Peritonectomy Procedures (Sugarbaker Technique)

• Greater Omentectomy / Splenectomy / Distal Pancreatectomy (often en bloc).
• Right/Left Upper Quadrant Peritonectomy: Stripping Glisson’s capsule, diaphragm stripping/resection.
• Pelvic Peritonectomy: Rectosigmoid resection, uterine/ovarian resection, bladder resection, pelvic side wall stripping.
• Cholecystectomy (routine portal for HIPEC catheter).
• Appendectomy / Right Hemicolectomy (en bloc with primary tumor).
• Small Bowel Resections: Multiple enterotomies for mucosal stripping vs resection.

HIPEC Parameters (Critical Variables)

Note on MMC vs Oxaliplatin: MMC is heat-stable, DNA crosslinker, long half-life in tissue (good for low grade). Oxaliplatin has synergistic cytotoxicity with heat**, short half-life, less myelosuppression (better for high grade where systemic chemo follows quickly).

Completeness of Cytoreduction (CC) Score

• CC-0: No visible disease.
• CC-1: Nodules < 2.5 mm (penetration depth of heat/chemo).
• CC-2: Nodules 2.5 mm – 2.5 cm.
• CC-3: Nodules > 2.5 cm / Unresectable.
• Survival Benefit: Only CC-0/1 offers long-term survival. CC-2/3 = Palliative debulking only.

10. Surveillance and Follow-Up

No universal guidelines; protocols vary by histology and treatment intensity.

Neuroendocrine Tumors (NET G1/G2)

• Post-Appendectomy (Curative): CT Abdomen/Pelvis at 3-6 months, then annually x 3-5 yrs (optional if <1cm tip).
• Post-Hemicolectomy / Metastatic: CgA, Urine 5-HIAA q 6-12 mo. Ga-68 DOTATATE PET/CT or CT/MRI q 6-12 mo x 5-10 yrs (indolent course).

LAMN (Confined, R0)

• Minimal/No Surveillance. Some centers: Single CT at 12 months. Colonoscopy at 1 yr (screening interval).

LAMN (Ruptured/Margins+) / PMP (Post CRS/HIPEC) / GCA / Adenocarcinoma

• Intensive Surveillance (High Recurrence Risk):
• History/Physical + Tumor Markers (CEA, CA 19-9, CA 125): q 3-6 mo x 3 yrs, q 6-12 mo x 2-5 yrs.
• Imaging (CT Chest/Abd/Pelvis or MRI Abd/Pelvis): q 6 mo x 3 yrs, then annually to 5-10 yrs.
• Diagnostic Laparoscopy: Controversial. Some centers offer at 12-24 months post-CRS/HIPEC for PCI=0 reassurance (especially if pre-op PCI high).
• Colonoscopy: 1 year post-op, then q 3-5 yrs (screening for metachronous colonic lesions).

11. Prognosis and Survival Outcomes

Survival is heavily dependent on Histology, Grade, Stage, and Completeness of Resection (CC Score).

12. Special Clinical Scenarios

Pregnancy

• Diagnosis: MRI preferred (no radiation). Tumor markers (CEA/CA19-9) less reliable.
• Surgery: 2nd Trimester (14-24 wks) is safest window for appendectomy/hemicolectomy.
• LAMN/NET: Delay definitive surgery (hemicolectomy/CRS) until postpartum if diagnosed late 3rd trimester / low burden.
• Aggressive Cancer (MAC/GCA): Treat per standard guidelines; multidisciplinary decision balancing maternal/fetal risk. CRS/HIPEC contraindicated in pregnancy.

Pediatric / Adolescent Appendiceal Neoplasms

• Extremely rare. NETs most common.
• LAMN/PMP reported but very rare.
• Management principles same as adults; fertility preservation paramount (ovarian transposition, oocyte cryopreservation before CRS/HIPEC).

Fertility Preservation (Young Women)

• CRS/HIPEC: Often requires hysterectomy/BSO (ovaries common site for mucinous implants).
• Options: Oocyte/Embryo Cryopreservation before surgery/chemo. Ovarian Transposition (Oophoropexy) laterally out of pelvis (limited utility if whole abdomen treated). Uterine preservation possible if no direct invasion, but HIPEC effects on uterus/ovaries (premature ovarian failure) are significant.
• Counseling: Mandatory referral to Reproductive Endocrinology before neoadjuvant therapy or CRS/HIPEC.

13. Emerging Therapies and Future Directions

1. PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy): Minimally invasive, repeated laparoscopic delivery of aerosolized chemo (Cisplatin/Doxorubicin or Oxaliplatin). For unresectable PMP/PMCA to downstage for CRS or palliative control. Promising response rates in low-grade PMP.
2. Targeted Therapy based on Molecular Profiling:

• HER2+: Trastuzumab Deruxtecan (DESTINY-CRC02 subset).
• BRAF V600E: Encorafenib + Cetuximab (BEACON regimen).
• NTRK Fusions: Larotrectinib/Entrectinib.
• FGFR Inhibitors: For FGFR2 fusions (rare).

1. Immunotherapy: Pembrolizumab/Dostarlimab for dMMR/MSI-H tumors (agnostic approval). Response rates >40% in appendiceal cancer.
2. Neoadjuvant Systemic Therapy: FOLFOXIRI + Bevacizumab or FOLFOX + Panitumumab (RAS WT) to downstage borderline resectable peritoneal disease (clinical trials ongoing: e.g., PERISCOPE II, CAIRO6 appendiceal cohorts).
3. Liquid Biopsy (ctDNA): Monitoring Minimal Residual Disease (MRD) post-CRS/HIPEC or post-resection to guide adjuvant therapy decisions.
4. Organoid Models: Patient-derived organoids for drug sensitivity testing (personalized medicine).

14. Patient Education and Quality of Life

• Nutrition: Critical pre/post CRS/HIPEC. High protein, calorie dense. TPN often needed perioperatively. Dietitian involvement mandatory.
• Stoma Care: High rate of temporary (ileostomy/colostomy) or permanent stomas after CRS/HIPEC (pelvic peritonectomy/resection). Enterostomal therapy (ET) nursing support essential.
• Psychosocial: Rare disease isolation. Connect with Appendiceal Cancer Support Groups (e.g., Appendix Cancer PMP Research Foundation – ACPMP, Pseudomyxoma Survivor).
• Financial Toxicity: CRS/HIPEC + prolonged recovery = significant cost. Social work navigation.
• Long-term Sequelae: Chronic bowel dysfunction (diarrhea, obstruction risk), neuropathy (Oxaliplatin), premature menopause (females), hernia formation at laparotomy site.

15. Summary of Key Takeaways for Clinicians

1. “Appendiceal Neoplasm” is not a single diagnosis. Demand specific histology (LAMN vs HAMN vs MAC vs GCA vs NET) and grade.
2. LAMN ≠ Cancer (if confined). Do not over-treat pTis LAMN R0 with hemicolectomy or adjuvant chemo. Simple appendectomy is curative.
3. Rupture changes everything. Intraoperative spillage of mucin converts localized disease to Stage IV (M1a). Frozen section for mucoceles is standard of care.
4. GCA requires Hemicolectomy + BSO. Never treat with simple appendectomy.
5. CRS/HIPEC is for Selected Patients. Requires expertise, low PCI, favorable histology, and goal of CC-0/1. It is not palliative debulking.
6. Molecular Testing is Standard. MMR/MSI, RAS, BRAF, HER2, NTRK on all adenocarcinomas/GCA.
7. Refer to High-Volume Centers. Outcomes for PMP and advanced appendiceal cancer are directly correlated with center volume and surgeon experience.
8. Surveillance is Histology-Specific. Do not follow a NET like an adenocarcinoma, or LAMN like a GCA.

References

• Amin, M.B., Edge, S.B., Greene, F.L., et al. (eds.) (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
• Bandyopadhyay, S., et al. (2023) ‘Goblet cell adenocarcinoma of the appendix: A comprehensive review’, Journal of Surgical Oncology, 127(5), pp. 842-853. doi: 10.1002/jso.27189.
• Baratti, D., et al. (2020) ‘Management of appendiceal neoplasms: A review’, Journal of the National Comprehensive Cancer Network, 18(9), pp. 1248-1257. doi: 10.6004/jnccn.2020.0045.
• Bradley, R.F., Stewart, J.H.T., Russell, G.B., et al. (2006) ‘Pseudomyxoma peritonei of appendiceal origin: A clinicopathologic study of 101 patients uniformly treated at a single institution’, Annals of Surgical Oncology, 13(10), pp. 1270-1278.
• Carr, N.J., Cecil, T.D., Mohamed, F., et al. (2016) ‘A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia’, The American Journal of Surgical Pathology, 40(1), pp. 14-26.
• Chandrakumaran, K., et al. (2021) ‘Systemic therapy for advanced appendiceal adenocarcinoma: A systematic review’, Journal of Gastrointestinal Oncology, 12(4), pp. 1892-1905. doi: 10.21037/jgo-21-88.
• Cheung, Y.S., et al. (2022) ‘Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for appendiceal neoplasms: A systematic review’, Surgical Oncology, 40, 101655. doi: 10.1016/j.suronc.2021.101655.
• Chua, T.C., et al. (2012) ‘Systematic review of the survival and prognosis of appendiceal mucinous neoplasms by histologic subtype’, Annals of Surgical Oncology, 19(3), pp. 938-948.
• Dotan, E., et al. (2022) ‘NCCN Guidelines Insights: Colon Cancer, Version 2.2022 (Appendiceal Adenocarcinoma section)’, Journal of the National Comprehensive Cancer Network, 20(5), pp. 469-476.
• Gomez, D., et al. (2023) ‘Molecular characterization of appendiceal cancers reveals distinct subsets with therapeutic implications’, Nature Communications, 14, 1234. doi: 10.1038/s41467-023-36890-1.
• Govaert, K.M., et al. (2020) ‘Systemic therapy in metastatic appendiceal cancer: A retrospective multicenter cohort study’, Annals of Oncology, 31(1), pp. 123-130.
• Hof, J.D., et al. (2019) ‘The prognosis of appendiceal neoplasms: A population-based study’, Annals of Surgical Oncology, 26(13), pp. 4321-4329.
• Kanthan, R., et al. (2015) ‘Appendiceal neoplasms: A review’, World Journal of Gastroenterology, 21(36), pp. 10344-10354.
• Klaver, C.E.L., et al. (2019) ‘Treatment of pseudomyxoma peritonei with cytoreductive surgery and HIPEC: A systematic review of survival and quality of life’, Annals of Surgical Oncology, 26(12), pp. 4088-4099.
• Lino-Silva, L.S., et al. (2019) ‘Goblet cell carcinoma of the appendix: A clinicopathologic study of 63 cases’, Human Pathology, 83, pp. 156-164.
• McCusker, M., et al. (2002) ‘Appendiceal carcinoids: A review of the literature’, American Surgeon, 68(10), pp. 935-940.
• Misdraji, J., et al. (2012) ‘Low-grade appendiceal mucinous neoplasms: A clinicopathologic analysis of 62 cases’, The American Journal of Surgical Pathology, 36(1), pp. 133-143.
• Mohamed, F., et al. (2011) ‘Clinicopathologic analysis of 224 patients with low-grade mucinous neoplasms of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy’, Annals of Surgical Oncology, 18(12), pp. 3345-3352.
• Moran, B.J. (2015) ‘Management of pseudomyxoma peritonei’, British Journal of Surgery, 102(2), pp. 125-136.
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) (2024) Appendiceal Adenocarcinoma. Version 1.2024. National Comprehensive Cancer Network. Available at: https://www.nccn.org (Accessed: 15 October 2024).
• Overman, M.J., et al. (2017) ‘Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study’, The Lancet Oncology, 18(9), pp. 1182-1191. (Includes appendiceal cohort).
• Paakkonen, M., et al. (2019) ‘Treatment of appendiceal cancer: A systematic review’, Scandinavian Journal of Surgery, 108(1), pp. 14-22.
• Prabhudesai, A., et al. (2021) ‘Neuroendocrine tumors of the appendix: A SEER database analysis’, Journal of Surgical Research, 260, pp. 277-284.
• Randle, R.W., et al. (2020) ‘Factors associated with survival after cytoreductive surgery and HIPEC for appendiceal cancer’, Journal of Surgical Oncology, 122(5), pp. 855-862.
• Ronnett, B.M., et al. (1995) ‘The morphological spectrum of ovarian metastases of appendiceal adenocarcinomas: A clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors’, Human Pathology, 26(1), pp. 31-41.
• Sugarbaker, P.H. (2016) ‘Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal mucinous neoplasms’, Journal of Gastrointestinal Oncology, 7(4), pp. 583-592.
• Turaga, K.K., et al. (2014) ‘Impact of pattern of metastatic spread on outcomes in appendiceal adenocarcinoma’, Annals of Surgical Oncology, 21(7), pp. 2258-2264.
• Vimalachandran, D., et al. (2017) ‘Malignant neoplasms of the appendix: A review’, International Journal of Colorectal Disease, 32(1), pp. 1-10.
• WHO Classification of Tumours Editorial Board (2022) Digestive System Tumours. 5th edn. Lyon: International Agency for Research on Cancer (WHO Classification of Tumours Series).
• Yan, T.D., et al. (2007) ‘A novel tumor-node-metastasis (TNM) classification for cancer of the appendix’, Annals of Surgical Oncology, 14(3), pp. 1074-1080.